Go Back   SEQanswers > Literature Watch

Similar Threads
Thread Thread Starter Forum Replies Last Post
PubMed: Sample preparation for small RNA massive parallel sequencing. Newsbot! Literature Watch 0 09-23-2011 09:13 PM
PubMed: Scalable transcriptome preparation for massive parallel sequencing. Newsbot! Literature Watch 0 07-17-2011 05:31 AM
PubMed: Decoding a substantial set of samples in parallel by massive sequencing. Newsbot! Literature Watch 0 07-06-2011 03:00 AM
RNA-Seq: Identification of fusion genes in breast cancer by paired-end RNA-sequencing Newsbot! Literature Watch 0 01-21-2011 05:50 AM
Massive parallel amplicon sequencing on Illumina GA Khen Khermesh General 3 07-09-2010 06:44 AM

Thread Tools
Old 02-10-2011, 07:10 AM   #1
RSS Posting Maniac

Join Date: Feb 2008
Posts: 1,439
Default PubMed: Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRC

Syndicated from PubMed RSS Feeds

Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations.

Hum Mutat. 2011 Jan 25;

Authors: De Leeneer K, Hellemans J, De Schrijver J, Baetens M, Poppe B, Van Criekinge W, De Paepe A, Coucke P, Claes K

This study describes how the new massive parallel sequencing technology can be implemented in a diagnostic setting for the breast cancer susceptibility genes (BRCA1 and BRCA2). The throughput was maximized by increasing uniformity in coverage, obtained by a multiplex approach, which outperformed pooling of singleplex PCRs. We evaluated the sensitivity by analysis of 133 distinct sequence variants; three (2%) deletions or duplications in homopolymers of greater than or equal to seven nucleotides remained undetected, illustrating a limitation of pyrosequencing. Furthermore, other limitations like nonrandom sequencing errors, pseudogene amplification, and failure to detect multiexon deletions are thoroughly described. Our workflow illustrates the potential of massive parallel sequencing of large genes in a diagnostic setting, which is of great importance to meet the increasing expectations of genetic testing. Implementation of this approach will hopefully lead to a strong reduction in turnaround times. As a consequence a wider spectrum of at risk women will be able to benefit from therapeutic interventions and prophylactic interventions. Hum Mutat 31:1-10, 2011. 2011 Wiley-Liss, Inc.

PMID: 21305653 [PubMed - as supplied by publisher]

Newsbot! is offline   Reply With Quote

Thread Tools

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

All times are GMT -8. The time now is 07:16 AM.

Powered by vBulletin® Version 3.8.9
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Single Sign On provided by vBSSO